Lotrim

Quick links to important sections

Lotrim

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lotrim

Quick Facts

Property Description
Active ingredient Clotrimazole
Common Forms Cream, solution, vaginal tablet
Pharmacological class Azole antifungal agent
Origin Synthetic compound
General Purpose Controlling superficial fungal infections

What is Clotrimazole and What Type of Medicine is Lotrim?

Lotrim is a widely recognized brand name for the medication identified by its primary active ingredient, Clotrimazole, which functions as an antifungal agent. This compound is chemically classified as a synthetic imidazole derivative, belonging to the larger family of azole antifungals, a group clinically recognized for their effectiveness against a broad range of pathogenic fungal organisms. Lotrim's general purpose is rooted in stopping the growth and facilitating the elimination of susceptible dermatophytes and yeasts responsible for common superficial infections, such as those affecting the skin or mucous membranes. This medicine is often available over-the-counter (OTC) in its topical forms, differentiating it from prescription-only agents.

Composition and Available Pharmaceutical Preparations

The active substance, Clotrimazole, is formulated within various pharmaceutical preparations to ensure precise delivery. Clotrimazole is incorporated into different bases/vehicles—such as oil-in-water or water-in-oil cream emulsions, alcohol-based solutions, and lighter lotion formulations—to suit the targeted area. The main dosage forms available include these topical preparations, primarily designed for dermal use, alongside specialized forms such as vaginal tablets (pessaries) for intravaginal administration and lozenges (troches) intended for use in the mouth (oral transmucosal application). Formulating Clotrimazole in these diverse preparations is key to optimizing the compound’s essential contact with the pathogenic organism.

Regulatory References

  1. Clotrimazole Topical: MedlinePlus Drug Information

What side effects are possible with Lotrim?

Possible Side Effects and Safety Information

The official safety profile for Clotrimazole (the active ingredient in Lotrim) is primarily characterized by localized application site reactions, which reflects the minimal systemic absorption of the drug following topical use. Adverse reactions are grouped according to standard regulatory System Organ Classes (SOCs).

Local effects are predominantly classified under Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions. Reactions such as a burning sensation, stinging, erythema (redness), pruritus (itching), and general skin irritation are commonly documented in regulatory labeling. For intravaginal forms, effects may include vulvovaginal discomfort, pain, or discharge.


Serious Adverse Reactions and Systemic Safety

While most effects are localized, the potential for rare, severe systemic reactions is documented under Immune System Disorders. These include anaphylactic reactions and angioedema (swelling beneath the skin), which may involve associated symptoms like hypotension or syncope.

Population and Interaction Constraints

Regulatory texts note that due to minimal absorption, harmful effects are considered unlikely during pregnancy and lactation, though use should occur under professional supervision. Safety constraints also exist regarding the formulation's interaction with materials: Clotrimazole (vaginal preparations) may reduce the effectiveness and safety of latex contraceptives. Furthermore, a high-level safety note is documented regarding potential increased plasma levels of oral tacrolimus or sirolimus when administered concurrently.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that an overdose of the topical form of Lotrim (clotrimazole) is generally not expected to be dangerous due to minimal absorption through the skin into the bloodstream. Systemic toxicity from excessive application is highly unlikely.

However, the primary overdose risk associated with this product is the accidental swallowing or ingestion of the medicine. In this case, the product is classified as potentially harmful if swallowed and may affect the gastrointestinal system.


Summary of Official Overdose Guidance

Overdose Scenario Regulatory Guidance Emergency Action
Topical Overuse Not expected to be dangerous. No urgent action typically required.
Accidental Swallowing/Ingestion Considered harmful if swallowed. Call a poison control center right away or seek immediate medical care.

If you believe that you or someone else has taken too much of this medicine, or if anyone has accidentally swallowed the medicine, you must call a poison control center immediately. Get medical care right away, even if the person who swallowed the medicine does not show any signs of discomfort or illness. This guidance ensures that necessary steps can be taken immediately following ingestion, as advised by regulatory authorities.

Therapeutic Uses of Lotrim

What Lotrim Treats: Main Uses and Benefits

Lotrim is indicated for the management of various common fungal infections of the skin. The main active ingredient, clotrimazole, is an antifungal agent designed to help relieve symptoms associated with dermatophyte and yeast conditions. The medication is used for treating conditions such as athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis).

The primary clinical benefit a patient receives is symptom relief, which includes helping to reduce the bothersome discomfort of scaling, cracking, burning, and itching. This topical medicine is commonly used to address the physical signs of these fungal skin conditions.

“The primary goal of topical antifungal use is to lessen the patient's discomfort and support symptom relief.”


Quick Fact: Relief for Itching Lotrim is used to manage the fungal overgrowth that contributes to skin irritation and associated symptoms across multiple common tinea conditions.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lotrim?

This section describes the officially documented population eligibility rules for Lotrim (Clotrimazole) based on government regulatory labeling, specifying who is permitted, restricted, or prohibited from use.

Eligibility and Restrictions

Category Regulatory Status
Absolute Contraindication Use is contraindicated in individuals with a known hypersensitivity or allergy to clotrimazole or to any of the specific excipients in the formulation.
Pediatric Use (Topical) Use is established in children and adolescents 3 years of age and older. Use in children under 3 years is generally not established and requires medical advice.
Pediatric Use (Vaginal Form) Not for use in girls under 12 years of age, except under the direction of a medical practitioner.
Pregnancy Use is preferably avoided during the first trimester. Use in the second and third trimesters may be considered when clearly necessary.
Lactation Use should be approached with caution, but systemic absorption is minimal. Avoid applying the cream directly to the breast area.
Site-Specific Restriction Topical preparations are not effective for fungal infections of the nails (onychomycosis) or the scalp (tinea capitis), which require systemic treatment.

Eligibility for adults is established for topical and vaginal indications. Due to minimal systemic absorption, official labeling generally does not document specific restrictions based on hepatic or renal impairment for the topical form.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Clotrimazole (the active ingredient in Lotrim) identifies specific interactions with certain products and medicines, primarily based on the product’s intended use and documented pharmacological effects.


Interaction Scope

Classification Interacting Substance / Product Documented Outcome / Restriction
Restricted Co-use (Local Integrity) Latex Contraceptive Devices (condoms, diaphragms, cervical caps), Spermicides The product may cause physical damage to latex material, documented to reduce their effectiveness for at least five days [SmPC / FDA].
Monitoring Required (Exposure Altering) Oral Immunosuppressants (Tacrolimus, Sirolimus) Co-administration may increase plasma concentrations of these medicines, requiring close therapeutic monitoring by a healthcare professional [FDA / SmPC].
Antagonism (Efficacy Reduction) Other Topical Antifungals (Polyene Antibiotics), High-Dose Dexamethasone Documented potential for reduced antifungal effect when used concurrently [SmPC].
Data-Deficient Assessment Herbal Remedies and Supplements Regulatory agencies note insufficient information to assess safety or effect on other medicines [NIH / MHRA].

Interaction-Related Constraints

Timing-based rules require patients using the vaginal formulation to utilize alternative contraceptive precautions for at least five days following treatment to avoid the risk associated with compromised latex integrity. Additionally, for systemically absorbed forms of Clotrimazole, patients with hepatic impairment are noted to require periodic monitoring of liver function test values due to documented adverse reports. These documented statements establish procedural constraints and monitoring requirements.

Mechanism of Action

How Lotrim Works

The mechanism of action for Lotrim (Clotrimazole) involves specific interference with the fungal metabolic processes. The drug's activity results in both fungistasis (inhibition of growth) and fungicidal action (destruction of the organism), dependent on the concentration achieved at the site of action.

Molecular Targeting: Blocking Ergosterol Biosynthesis

Clotrimazole acts as a direct inhibitor of the key fungal enzyme, lanosterol 14-alpha-demethylase (CYP51). This enzyme catalyzes a necessary step in the fungal ergosterol biosynthesis pathway. By binding to the enzyme, the drug prevents the conversion of lanosterol into the vital structural sterol, ergosterol. This primary molecular intervention initiates the sequence of cellular damage and structural failure.

Mechanistic Cascade: Cell Membrane Collapse

The inhibition of CYP51 results in the depletion of functional ergosterol and the subsequent accumulation of structurally toxic sterols within the fungal cell membrane. The presence of toxic sterols and absence of ergosterol lead to the destabilization and increased permeability of the membrane. The resulting failure of the osmotic barrier causes the leakage of essential intracellular components, such as potassium and phosphorus, leading to irreversible cellular damage.

Mechanism-Dependent Penetration Constraints

The action of this mechanism is dependent on the drug's ability to achieve and sustain sufficiently high concentrations at the site of the fungal pathogen. In areas protected by dense physiological barriers, such as the highly keratinized nails or hair shafts, the mechanism is constrained due to inadequate drug penetration and access to the target organism.

Dosage and Administration Information

Instruction Map: How to use Clotrimazole — Administration Guidelines

The usage of Clotrimazole, the active ingredient in Lotrim, is determined by its specific pharmaceutical preparation, with instructions detailing the route, dose, and administration technique.


Administration Scope

Feature Guideline
Route of administration Topical/Dermal, Intravaginal, and Oral Transmucosal (Lozenge).
Dosing schedule Topical 1% Cream/Solution: Applied twice daily. Intravaginal: Regimens include 500 mg as a single dose, 200 mg once daily for 3 days, or 100 mg once daily for 7 days.
Timing in relation to meals (if applicable) The oral transmucosal lozenge is held in the mouth until dissolved; there are no specific systemic administration requirements related to meal timing.
Preparation requirements (if applicable) Formulations are ready-to-use; no reconstitution or dilution is required. Vaginal creams and tablets may require an applicator for insertion.
Age-group administration rules Topical: Not for use in children under 2 years unless directed by a physician. Vaginal: Only for children aged 12 years and older.
Missed-dose rules For multi-dose regimens, the application should be made as soon as possible, but if it is nearly time for the next scheduled dose, the missed dose should be skipped.
Special procedural conditions Topical forms must be gently massaged into the affected and surrounding skin areas. Intravaginal applications are advised at bedtime. Oral lozenges must dissolve slowly and must not be chewed or swallowed whole.

Instruction Classifications (High-Level)

Classification Description
Administration method type Local (Dermal, Intravaginal, Oral Transmucosal).
Frequency pattern Daily (Once daily for vaginal; twice daily for topical; three or five times daily for oral lozenge).
Standardization Established pharmaceutical protocols.
Use-context constraints Duration ranges from 1 day (vaginal 500 mg) to 4 weeks (topical Tinea corporis).

Resulting procedural structure

Step sequence (key steps):

  • Apply a thin layer of the cream or solution to the cleaned, affected skin area.
  • Gently massage the topical preparation into the site of application.
  • Insert the intravaginal cream or tablet high into the vagina, typically at night.
  • Place the oral lozenge in the mouth and allow it to dissolve completely and slowly.

Connection to the overall use protocol: Usage is highly specific to the route, defining the dose, the required number of daily applications, and the total duration of the course (e.g., 2 weeks for jock itch versus 4 weeks for athlete's foot). This structure ensures standardized administration based on the intended local site of action.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lotrim

Evidence for Topical Use in Tinea Infections (Athlete's Foot, Ringworm, Jock Itch)

The research base for Lotrim's active ingredient, Clotrimazole, primarily consists of short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies included adults and, in some cases, children, diagnosed with fungal skin conditions, including athlete's foot, ringworm, and jock itch. Researchers monitored outcomes related to fungal clearance and the assessment of visible signs and reported symptoms. Research describes patterns measured at the conclusion of the study period, typically ranging from two to four weeks. Some research explored outcomes related to physical discomfort when comparing topical clotrimazole against an inactive substance (placebo) or against other topical agents.

Evidence for Intravaginal Use in Yeast Infections

The research base for clotrimazole in its intravaginal forms, evaluated for uncomplicated vulvovaginal candidiasis (yeast infection), is mainly derived from RCTs and systematic reviews. These research scenarios focused on non-pregnant adult women with a clinically and microbiologically confirmed diagnosis. Studies explored outcomes linked to inflammatory or irritative states and monitored patterns related to recurrence over defined time intervals following the initial research period.

Durability of Response and Long-Term Follow-up

For all indications, the research is more developed in assessing short-term symptom changes and clearance rates immediately following the conclusion of treatment. Research exploring long-term symptom changes and the durability of the initial outcome, especially six months or more after treatment, is less extensive. This lack of detailed data for long-term outcomes means that findings describing patterns of enduring symptom control are not fully established.

Evidence in Specific Study Populations

Clotrimazole has been evaluated in some research contexts involving children for common fungal skin infections, and findings suggest that the patterns observed in these studies were comparable to those described in adult populations. For older adults, there is limited specific information comparing their outcomes to younger adults, but research has limited information for these populations. Data for certain groups remain insufficient; for instance, there are few data available that monitor research outcomes related to this medication while breastfeeding. As a result, the findings describe patterns observed solely within the studied populations.

Evidence Gaps: What is Still Uncertain About Lotrim Research

A primary limitation across the entire research landscape is the variability in evidence quality and consistency. Many studies for tinea infections are constrained by modest sample sizes, and the methods used to measure and report outcomes have not been consistent across all research efforts. Comparative evidence exploring differences between clotrimazole formulations or against other compounds is limited, meaning certain comparisons are uncertain.

Key Studies & References CLOTRIMAZOLE 1% - clotrimazole cream (Official FDA Label/DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Lotrim (FAQ)


Q: Are there any signs that a possible side effect of Lotrim requires medical attention?

Official regulatory information indicates that most side effects from topical Lotrim are localized and mild. However, if blistering, significant swelling, hives, cracking, or severe irritation occurs, stopping use is indicated. These symptoms are documented as potentially requiring attention from a healthcare professional.


Q: Why are there different types of Lotrim (e.g., cream, powder, spray)?

Lotrim is manufactured in different pharmaceutical forms—such as cream, solution, and vaginal inserts—intended to allow the medication to be appropriately applied to the affected area. Regulatory information suggests that this variety assists in establishing optimal contact with the fungal organism, and different administration regimens are sometimes used to aid in patient compliance.


Q: What should be considered if the infection returns shortly after stopping the use of Lotrim?

If a fungal infection persists or returns shortly after the full course of treatment has been completed, official product information advises seeking medical help. Recurrent fungal infections can sometimes indicate a more complex medical situation that requires specialized care.


Q: Are there any specific safety considerations for elderly individuals using Lotrim?

Regulatory labeling for the primary ingredient in Lotrim generally notes that studies performed to date have not demonstrated problems unique to the elderly population. However, because older adults may be more likely to have conditions like thinning skin or skin ulcers, caution may be noted for topical use on these areas.


Q: Are the instructions for Lotrim the same for all types of fungal infections?

No. Official instructions state that while the frequency of application (such as twice daily for many topical forms) may be consistent, the required total duration of treatment is often different. The required course of use is specific and depends on the location and type of fungal infection being addressed.


Q: Can using Lotrim cause the treated skin area to look dry or peel?

Official safety documentation lists peeling, scaling, and skin dryness (exfoliation) as possible local reactions that may be associated with the use of topical clotrimazole.


Q: Is Lotrim safe for use on sensitive skin or on the face?

Official usage instructions advise that the topical product is not intended for use in the eyes. Contact with other mucous membranes, such as the mouth and lips, is also advised to be avoided.


Q: Does applying a thicker layer of Lotrim cream make it work faster or better?

Regulatory guidance instructs users to apply a thin layer or a quantity sufficient only to cover the affected area and the surrounding skin. Applying a thicker layer is generally discouraged, as it does not typically increase the medication's effectiveness and may instead increase the chance of local irritation.


Q: How soon can a person expect to see the first signs of improvement after using Lotrim?

Research indicates that early relief from skin symptoms may be observed within 2 to 3 days after starting the treatment course. However, achieving full clearance is contingent upon following the medication’s complete specified duration.


Q: What is the reason for having to continue Lotrim treatment after symptoms have cleared up?

Official sources state that continuing the product for the full duration is crucial even after symptoms disappear. This practice is described as important to ensure that all of the fungal organism is eliminated, helping to prevent the infection from returning (recurrence).


Q: Can a person with diabetes use Lotrim without special precautions?

Official regulatory information from certain authorities advises that individuals with diabetes are advised to consult a healthcare professional before use of the medication.


Q: Can Lotrim be used on open skin, cuts, or broken areas?

Official safety documentation states that topical preparations are generally not intended for use on broken skin, open cuts, or large areas of skin injury.


Q: Is it necessary to use a special soap or cleaner on the affected area before applying Lotrim?

Official instructions for application require that the affected skin area must be cleaned and dried thoroughly before the medicine is applied. However, regulatory instructions do not mandate the use of a special or specific brand of soap or cleaner.


Q: What should a person do if Lotrim is accidentally ingested or swallowed?

If the medication is accidentally swallowed, official safety warnings document that immediate contact with a Poison Control Center or seeking emergency medical help is advised.


Q: Why is Lotrim sometimes sold combined with another ingredient like a mild steroid?

Combination products contain an added ingredient, such as a mild steroid (like hydrocortisone), alongside the antifungal. Regulatory labeling indicates the purpose of the steroid is to help relieve associated symptoms of the infection, such as inflammation, redness, and itching.


Q: Is Lotrim effective for conditions that are not fungal, such as eczema or psoriasis?

The primary ingredient in Lotrim is officially indicated for the treatment of susceptible fungal infections, such as tinea and candidiasis. It is indicated solely for the treatment of susceptible fungal infections, and is not generally used for non-fungal conditions like eczema or psoriasis.


Q: Can the effectiveness of Lotrim be reduced by wearing tight clothing or closed-toe shoes?

Regulatory instructions suggest avoiding bandaging, wrapping, or covering the treated area with tight-fitting clothing unless directed otherwise. This is a general cautionary measure associated with the topical application of this class of medication.


Q: What is the main reason for drying the infected area completely before applying Lotrim?

Regulatory instructions strictly require that the affected area must be cleaned and dried thoroughly before the product is applied. This preparation is a required step that helps the medication work effectively on the skin's surface and helps to maintain a local environment unsuitable for fungal growth.


Q: Is there a risk of the fungal infection spreading while using Lotrim?

Official instructions advise washing hands thoroughly before and after applying the cream. This practice is documented as being important to help prevent the risk of spreading the fungal infection to other body areas or to other people.


Q: Why do some Lotrim products require a prescription while others are over-the-counter?

The classification of Lotrim products as over-the-counter or prescription-only depends on factors like the specific dosage strength, the intended route of use (such as vaginal forms), or the inclusion of a second active ingredient (like a corticosteroid). These differences in formulation and use determine whether medical supervision is generally required.

How should Lotrim be stored and disposed of?

Lotrim (clotrimazole) must be stored strictly according to official regulatory specifications to maintain its stability and prevent accidental exposure.

Storage Requirements

  • Temperature and Protection: The medication must be kept at controlled room temperature, typically 20 to 25 C (68 to 77 F), or sometimes up to 30 C (86 F), depending on the specific product. The container must be stored away from excess heat, moisture, and direct light. It is mandatory that the product not be frozen.
  • Container and Child Safety: The product must remain in its original container, tightly closed. The labeling explicitly requires storing the medicine out of the sight and reach of children.

Disposal Instructions

  • Unused Product: Do not use the product past the labeled expiration date. Disposal must not be via wastewater or household waste in many regions. The preferred method is a drug take-back program.
  • Alternative Disposal: If a take-back program is unavailable, follow US guidelines by mixing the medicine with an unappealing substance (like dirt or coffee grounds) in a sealed bag before placing it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lotrim found in:

A-Z Index: